Roivant Sciences Ltd. filings document material events for a Nasdaq-listed Bermuda biopharmaceutical company with common shares registered under the ticker ROIV. The company’s recent Form 8-K disclosures cover quarterly financial results, preliminary liquidity information, share repurchases, Regulation FD updates and exhibits tied to clinical programs at subsidiaries such as Priovant Therapeutics.
Its filings also record material definitive agreements and amendments, including the Genevant Sciences settlement agreement involving lipid nanoparticle delivery technology, as well as shareholder voting results from the annual general meeting. Governance disclosures include director elections, auditor ratification and other proxy-related voting matters, while clinical exhibits describe programs such as brepocitinib in autoimmune and inflammatory diseases.
Roivant Sciences Ltd. President & CIO Mayukh Sukhatme reported an exercise-and-sell pattern over two days. On June 25 and 26, he exercised options to acquire a total of 1,000,000 Common Shares at $3.85 per share and sold 1,000,000 Common Shares in open-market transactions.
The sales were executed at weighted average prices of $34.13 and $34.08 per share, each representing multiple trades within disclosed price ranges. Following these transactions, Sukhatme directly held 18,677,617 Common Shares. The underlying options exercised were fully vested and are no longer outstanding.
Roivant Sciences Ltd. reported insider transactions by President & Immunovant CEO Eric Venker involving both an option exercise and open-market sales of common shares.
Venker exercised stock options for 200,000 Common Shares at a conversion price of $3.85 per share and received fully vested shares. On the same date, he sold 46,234 Common Shares at a weighted average price of $33.51 and 153,766 Common Shares at a weighted average price of $33.05 in multiple open-market transactions within disclosed price ranges. Following these moves, he directly held 1,613,063 Common Shares and 4,244,834 stock options to purchase additional shares.
ROIV filed a Form 144 reporting the proposed sale of $17,039,650.00 worth of 500,000 shares via the Exercise of Options Under a Registered Plan. The filing cites an intended sale date of 06/26/2026 and lists cash as the method. The excerpt also shows 500,000 shares sold during the prior three months for $17,051,141.93.
Morgan Stanley Smith Barney LLC Executive Financial Services reported an intended sale of 500,000 shares of Common stock on 06/25/2026 under an Exercise of Options Under a Registered Plan. The filing lists the sale as routed through the issuer for cash and identifies NASDAQ as the exchange.
Roivant Sciences Ltd. filed a Form 144 disclosing proposed dispositions of Common Shares under Rule 144. The filing lists 200,000 shares associated with an options exercise (grant date 04/20/2022) and shows past sales of 200,000 shares on 04/20/2026 and 200,000 shares on 05/22/2026.
Roivant Sciences Ltd. CFO Richard Pulik reported a routine share disposition tied to equity compensation. On the RSU vesting date, 2,129 common shares at $31.43 per share were withheld by the company to satisfy tax withholding obligations through a net settlement of previously granted RSUs. Following this tax-related transfer, Pulik directly holds 276,420 common shares of Roivant Sciences Ltd.
Roivant Sciences Ltd. Chief Accounting Officer Jennifer Humes reported a routine tax-related share disposition. On this Form 4, 3,582 common shares were surrendered at a value of $31.43 per share to cover tax withholding tied to the vesting of previously granted RSUs. After this net settlement, she directly holds 109,782 common shares, indicating the transaction reflects compensation and tax obligations rather than an open-market sale.
Roivant Sciences Ltd. President & Immunovant CEO Eric Venker reported a set of transactions involving company shares. He exercised stock options to acquire 200,000 Common Shares at $3.85 per share, then sold 200,000 Common Shares in an open-market transaction at a weighted average price of $30.27 per share. Separately, 34,483 Common Shares were surrendered through a net settlement to cover tax withholding obligations on vested RSUs, which is not an open-market sale. After these transactions, Venker directly holds 1,613,063 Common Shares.